Inter-relationships Between COVID-19 and Metabolic Disorders

Guest Editors:

Giovanni Targher, MD
Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Alessandro Mantovani, MD
Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Special Issue Introduction:

During these two years of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, it has become increasingly clear that about 50% of patients who died from Coronavirus disease 2019 (COVID-19) had metabolic disorders, mainly obesity, type 2 diabetes, hypertension, or non-alcoholic fatty liver disease. Notably, experimental and observational studies have reported a complex and bidirectional relationship between COVID-19 and metabolic disorders. Indeed, on one side, patients with diabetes or other metabolic disorders have a higher risk of severe illness from COVID-19 and greater in-hospital mortality than those without metabolic disorders and, on the other side, COVID-19 may contribute to worse pre-existing metabolic disorders or even lead to new-onset diabetes or other metabolic disorders.

This Special issue of Metabolism and Target Organ Damage will focus on new experimental and epidemiological data in the area of the bidirectional links between COVID-19 and metabolic disorders. In particular, it will cover a selection of research and review articles on the following potential issues:

- Predisposition to severe illness from COVID-19 in patients with metabolic disorders;
- Effect of COVID-19 on metabolic and endocrine systems;
- Effect of environmental, economic, and social factors on the link between COVID-19 and metabolic disorders;
- Metabolic pathways possibly related to susceptibility and severity of COVID-19;
- Molecular mechanisms underpinning the link between COVID-19 and metabolic disorders;
- Role of nutritional status on the variability of COVID-19 susceptibility, course, and response to treatment;
- Long-term metabolic consequences of COVID-19;
- Effect of glucose-lowering medications on COVID-19 outcomes;
- Metabolic disorders and vaccine-breakthrough SARS-CoV-2 infection;
- Changes of thinking and management of metabolic diseases during and after the SARS-CoV-2 pandemic.

Experimental papers, epidemiological papers, up-to-date review articles, systematic reviews and meta-analyses, and commentaries are all welcome.

I hope you enjoy reading this edition of the journal.

Benefits to Authors:

- The APCs ($600) will be WAIVED;
- Provide Language Polishing Service by Native English Speakers. The fee is undertaken by the journal;
- Enjoy faster publication than regular submissions;
- Authors will be invited as Guest Speakers to our journal webinars. The webinar will be held via Zoom and it will also be broadcast live on Youtube and the Chinese WeChat Official Account, Video Account, Bilibili;
- A special interview will be provided to authors and will be promoted on the journal homepage and all media promotion platforms of both via the journal and publisher;
- Winner(s) of the "Best Paper Award" will be awarded. The reward will be in the form of a cash prize and a certificate.
Journal Introduction:

Metabolism and Target Organ Damage (M&TOD, https://mtodjournal.net/, ISSN: 2769-6375) is a journal newly launched in 2021 with fast development in the past few months. It is an international, peer-reviewed, open access interdisciplinary journal which provides an online platform for the publication of clinical, basic, and translational studies. It covers (cardio)-metabolic disorders per se, such as obesity, diabetes, dyslipidemias, arterial hypertension and hyperuricemia in all age groups.

Editorial Board team:

Scan the QR code to view the journal website